Fig. 2From: Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohortAssociations between estrogen plus progestin therapy (EPT) at baseline and risk of breast cancer, by estrogen and progesterone receptor status, among eligible postmenopausal women with intact uteri (n = 68,284) in the entire National Institutes of Health-AARP Diet and Health Study cohort (1996/1997–2011). BC, breast cancer. ER, estrogen receptor. PR, progesterone receptorBack to article page